Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis

Lupus Sci Med. 2024 May 28;11(1) doi: 10.1136/lupus-2024-001156

The combination of anti-dsDNA and anti-SSA/Ro60 serotype may help to foretell the patient’s renal response to belimumab. Investigators here aimed to explore the effectiveness of belimumab on active LN, exploring predictors, including serological biomarkers, of renal response to belimumab in a real-world setting.

This multicentre, real-world study of 122 patients provided further evidence of the effectiveness of belimumab as an add-on therapy for the Chinese LN population.

Keywords:


LinkedIn